This clinical trial is for men and women with high-grade gliomas. Glucose (sugar) is thought to be a contributor to tumor growth. The ketogenic diet (a high fat, low carbohydrate diet) and metformin (a drug approved by the Food and Drug Administration to treat type 2 diabetes) are both known to lower blood glucose levels.
Many studies are designed for people with specific diseases or conditions. Others are looking for healthy volunteers, and some studies enroll both individuals with diseases/conditions, as well as, healthy volunteers for comparison. Every clinical trial has detailed criteria that determine whether an individual is eligible to participate.
How Are Clinical Trial Participants Protected?
Before joining a study, participants undergo a process of Informed Consent, which includes discussion of the risks and potential benefits of participating in a study.
The institution conducting the research must utilize an Institutional Review Board (IRB). The IRB is made up of physicians, researchers, and community members. The board reviews every study before deciding if the study can move forward. The main focus of the IRB is to protect the rights and welfare of study participants. The IRB monitors each study, at least annually, throughout the life of the study.
The Food and Drug Administration (FDA) has strict regulations for the conduct of clinical trials to ensure the protection of study participants.
Two Weill Cornell Medicine scientists have received the Damon Runyon Cancer Research Clinical Investigator Award for 2016 for their innovative research.
A vaccine developed at Weill Cornell Medicine and NewYork-Presbyterian to blunt the effects of cocaine has advanced to clinical trials for testing in humans. After demonstrating that the vaccine prevented cocaine from reaching the brain in earlier animal studies, investigators are now enrolling active cocaine addicts in a Phase I randomized control study to test how it works in people.
At Weill Cornell Medicine, people are the heart and soul of our institution. Our faculty and staff — the physicians, scientists, and administrators who work so hard every day to fulfill our mission to care for patients, discover innovative cures and treatments, and teach the next generation of physicians — make us who we are.
NEW YORK, NY, July 8, 2016 — Columbia University Medical Center (CUMC) and Weill Cornell Medicine, in collaboration with NewYork-Presbyterian and NYC Health + Hospitals/Harlem, have been awarded a grant from the NIH for approximately $4 million in fiscal year 2016 to enroll participants in the Cohort Program of President Barack Obama's Precisi
Philip Stieg, M.D., Ph.D. and Lewis Cantley , Ph.D.
In many ways, it’s a science success story: 8-year-old boy with a rare form of brain cancer is treated by one of the world’s leading experts in the disease, who collaborates with a pioneering precision medicine institute to sequence his cancer and create a first-of-its-kind tumor model replica in the lab, allowing for further analysis and treatment testing without risk of harm to the child.
A new gene therapy developed by scientists at Weill Cornell Medicine could eventually prevent the life-threatening effects of peanut allergy with just a single dose, according to a new pre-clinical study.
The New York City Chapter of The Leukemia & Lymphoma Society (LLS) has announced John P. Leonard, MD, of Weill Cornell Medicine and NewYork-Presbyterian as its 2016 Manhattan Light The Night® corporate chair. Light The Night is LLS's largest annual fundraising event held each fall to find cures and provide access to treatments for blood cancer patients.
